EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma

Zachary Kaplan, Elizabeth Prezioso, Aditi Jain, Harish Lavu, Charles J Yeo, Wilbur B Bowne, Avinoam Nevler iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70960 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2025. Verfasst von Zachary Kaplan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Medical College, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, DNA Mismatch Repair, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic cancer is a highly aggressive and lethal disease, characterized by a limited response to chemotherapy and overall poor prognosis. Pancreatic cancers with a distinct mismatch repair deficiency, although relatively rare, have been shown to be associated with markedly better outcomes in comparison. Furthermore, whereas pancreatic cancers are generally unresponsive to current immunotherapy, this specific group of tumors has been shown to have a notable susceptibility to immune checkpoint inhibitors.

Aims

In this review, we aim to summarize the relevant literature regarding mismatch‐repair associated pancreatic cancers, the impacted biological mechanisms, and the resulting vulnerabilities for potential opportunistic immunotherapeutic treatment approaches. We will also review the current clinical studies assessing survival outcomes of mismatch repair deficient pancreatic cancers and ongoing clinical trials in this emerging field. Results and Conclusions Patients with dMMR/MSI‐H pancreatic cancers harbor a distinct phenotype that has increased immune activation, greater responsiveness to immune checkpoint inhibitor therapy and better overall survival when compared to other pancreatic cancers. Although this molecular subtype makes up a small minority of cases, emerging data suggest immunotherapy may offer benefit to these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsDNA Mismatch RepairCarcinoma, Pancreatic DuctalHumansImmune Checkpoint InhibitorsImmunotherapyPrognosisMicrosatellite Instability

Stichwörter der Autor:innen

DNA repairTMBclinical outcomesmicrosatellite instabilitymismatch repairpancreatic cancerpancreatic ductal adenocarcinoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Sidney Kimmel Medical College, Philadelphia, Pennsylvania, USA.
  • Jefferson Pancreatic, Biliary, and Related Cancer Center, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Avinoam Nevler

Zitieren

APA

Kaplan, Z., Prezioso, E., Jain, A., Lavu, H., Yeo, C. J., Bowne, W. B., & Nevler, A. (2025). Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.70960

Vancouver

Kaplan Z, Prezioso E, Jain A, Lavu H, Yeo CJ, Bowne WB, et al. Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma. Cancer Medicine. 2025. doi:10.1002/cam4.70960

BibTeX
@article{Kaplan2025,
  author = {Kaplan, Zachary and Prezioso, Elizabeth and Jain, Aditi and Lavu, Harish and Yeo, Charles J and Bowne, Wilbur B and Nevler, Avinoam},
  title = {Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70960}
}
Kostenlos starten →